Research & Development
Evoke Pharma receives USPTO Notice of Allowance for GIMOTI patent
14 September 2023 -

Pharmaceutical company Evoke Pharma Inc (NASDAQ:EVOK) announced on Thursday that it has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for its patent application related to GIMOTI (metoclopramide) nasal spray.

GIMOTI is the first FDA-approved nasal formulation of metoclopramide available in the United States.

When issued, the patent will cover the intranasal pharmaceutical composition of GIMOTI and will be set to expire in 2029.

According to Evoke Pharma, GIMOTI has demonstrated a meaningful reduction in utilization of healthcare resources and presents a novel solution to diabetic gastroparesis treatment by delivering a non-oral dose of metoclopramide to relieve symptoms in adults. GIMOTI has been commercially available in the United States since 2020 and is currently prescribed by over 1,000 healthcare providers nationwide.